Blog

Posts Tagged ‘biotech stocks’

Sangamo gets RMAT status for its hemophilia gene therapy

On July 5 Sangamo Therapeutics (SGMO) and partner Pfizer (PFE) announced update results of a Phase 1/2 study of Sangamo's SB-525 gene therapy for severe hemophilia A. The companies also announced that the U.S. Food & Drug Administration had granted regenerative medicine advanced therapy (RMAT) designation to SB-525. RMAT status is given to therapies intended […]

To subscribe to JAM you need to fill in some details below including, ahem, some info on how you'll pay us. A subscription is $199 (although if you're subscribing with one of our special offers it will be lower) for a year for ongoing and continuing access to the site. And we'll throw in the first week free! If you change your mind during that first week, just cancel your subscription from your profile page, and you won't be billed anything.

More talk about doing “something” about drug prices sends drug stocks down

It's good to know that in this sometimes confusing and volatile market some things remain constant. A high-profile figure says something about the need to lower drug prices and drug stocks tumble. Whether the "something" is likely to result in action or not. Today it was President Donald Trump telling reporters that his administration is […]

To subscribe to JAM you need to fill in some details below including, ahem, some info on how you'll pay us. A subscription is $199 (although if you're subscribing with one of our special offers it will be lower) for a year for ongoing and continuing access to the site. And we'll throw in the first week free! If you change your mind during that first week, just cancel your subscription from your profile page, and you won't be billed anything.

Special Report: 10 Best Picks for the Last Six Months of 2019

This isn't  time for investing as usual. As whacky as the first half of 2019 has been--the Federal Reserve embraces interest rate cuts, the U.S. and China descend further into a trade war, the U.S. economy turns in better than 3% growth but fears for a slowdown in global growth in 2019 and for a U.S. recession in 2020 […]

To subscribe to JAM you need to fill in some details below including, ahem, some info on how you'll pay us. A subscription is $199 (although if you're subscribing with one of our special offers it will be lower) for a year for ongoing and continuing access to the site. And we'll throw in the first week free! If you change your mind during that first week, just cancel your subscription from your profile page, and you won't be billed anything.

Adding Nektar call options to my Volatility Portfolio–again

Again. I'm adding the January 17, 2020 Call Options with a strike at $35 on Nektar Theraeutics (NKTR) to my Volatility Portfolio on JubakAM.com and JugglingWithKnives.com. (Ticker on these options is NKTR200117C00035000.) The underlying shares closed at $33.70, up 0.90% on June 14. I've traded these options before with a spectacular realized gain of better than […]

To subscribe to JAM you need to fill in some details below including, ahem, some info on how you'll pay us. A subscription is $199 (although if you're subscribing with one of our special offers it will be lower) for a year for ongoing and continuing access to the site. And we'll throw in the first week free! If you change your mind during that first week, just cancel your subscription from your profile page, and you won't be billed anything.

Incyte adds to Jakafi label with new FDA approval

Jubak Picks and Volatility Portfolio member Incyte (INCY) closed up 1.55% today to $81.75 on news that the U.S. Food and Drug Administration had approved the company's Jakafi for treatment for acute Graft versus Host disease (GvHD), an inflammatory response by the immune system after a bone marrow transplant. The drug can now be prescribed to […]

To subscribe to JAM you need to fill in some details below including, ahem, some info on how you'll pay us. A subscription is $199 (although if you're subscribing with one of our special offers it will be lower) for a year for ongoing and continuing access to the site. And we'll throw in the first week free! If you change your mind during that first week, just cancel your subscription from your profile page, and you won't be billed anything.

Making Incyte #9 on my 10 most dangerous stocks for earnings season Special Report–and #5 on my buy on any plunge Bonus Special Report

There's a good chance that Incyte (INCY) will miss Wall Street earnings and revenue projections when it reports first quarter results on April 30. That's because Incyte is a biotech adolescent. Think awkward. The company is old enough to have substantial revenue from one drug, Jakafi, an oral JAK (janus kinase) inhibitor. In the short […]

To subscribe to JAM you need to fill in some details below including, ahem, some info on how you'll pay us. A subscription is $199 (although if you're subscribing with one of our special offers it will be lower) for a year for ongoing and continuing access to the site. And we'll throw in the first week free! If you change your mind during that first week, just cancel your subscription from your profile page, and you won't be billed anything.

Making Nektar #8 on my list of 10 most dangerous stocks for earnings season–and #4 on my list of 5 to buy on any plunge

Nektar Therapeutics (NKTR) won't miss Wall Street earnings projections when it reports its first quarter financial results on May 9--because the company won't report any earnings. The consensus projection now has the company reporting a loss of 76 cents a share on revenue of $26.2 million. But that doesn't mean biotech Nektar isn't in danger […]

To subscribe to JAM you need to fill in some details below including, ahem, some info on how you'll pay us. A subscription is $199 (although if you're subscribing with one of our special offers it will be lower) for a year for ongoing and continuing access to the site. And we'll throw in the first week free! If you change your mind during that first week, just cancel your subscription from your profile page, and you won't be billed anything.

Volatility Portfolio member Sangamo pops 28.96% today on positive news in two trials.

Two big pieces of positive news popped shares of Sangamo Therapeutics (SGMO) today by 28.96% at the close. First, Sangamo announced interim data from its Hemophilia A program with Pfizer (PFE). The SB-525 gene therapy Phase 1/2 study in eight patients showed a dose-dependent increase in Factor VIII levels (indicating that the gene therapy was efficacious) […]

To subscribe to JAM you need to fill in some details below including, ahem, some info on how you'll pay us. A subscription is $199 (although if you're subscribing with one of our special offers it will be lower) for a year for ongoing and continuing access to the site. And we'll throw in the first week free! If you change your mind during that first week, just cancel your subscription from your profile page, and you won't be billed anything.

Adding Ionis Pharmacueticals to my Special Report: 10 Best Buy Stocks for After the Bear–and to my Volatility Portfolio

To subscribe to JAM you need to fill in some details below including, ahem, some info on how you'll pay us. A subscription is $199 (although if you're subscribing with one of our special offers it will be lower) for a year for ongoing and continuing access to the site. And we'll throw in the first week free! If you change your mind during that first week, just cancel your subscription from your profile page, and you won't be billed anything.

Syneos, another small cap stock to watch (or to buy if you think the bear is over)

Back on November 27, I launched a "Special Report: My 10 small company stock picks for the January Effect." What with tremendous volatility in the market, the beginning of a bear market for some sectors, and the failure of the January Effect to arrive on schedule in December, I never finished the list. I fact […]

To subscribe to JAM you need to fill in some details below including, ahem, some info on how you'll pay us. A subscription is $199 (although if you're subscribing with one of our special offers it will be lower) for a year for ongoing and continuing access to the site. And we'll throw in the first week free! If you change your mind during that first week, just cancel your subscription from your profile page, and you won't be billed anything.